Latest Breaking News On - Checkmate 914 trial - Page 1 : comparemela.com

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Dorothy byrneRobertj motzerGenitourinary oncology serviceMemorial sloan kettering cancer centerCancers symposiumKidney cancerDorothy byrne chairClinical oncologyMemorial sloan kettering cancerAdjuvant nivolumab monotherapyPatients with localized renal cell carcinomaCheckmate 914 trial